In particular, the adverse-risk group has been expanded to include seven additional mutations: BCOR, EZH2, SF3B1, SRSF2, STAG2, U2AF1, and ZRSR2—together with ASXL1 and RUNX1 (already included in ELN 2017)—forming the “myelodysplasia-related” (MR) gene group [6,7]. This evidence concerns the gene SF3B1 and Myelodysplasia.